Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

Share Price is delayed by 15 minutes
Get Live Data
145.50    1.00 (0.69%)
Bid:
144.00
Ask:
147.00
Spread: 3.00 (2.083%)
Market Cap: £123.14m
DXRX Live PriceLast checked at - London Stock Exchange

Intraday Diaceutics Share Chart

Directorate Change

22 Dec 2020 07:01

RNS Number : 4363J
Diaceutics PLC
22 December 2020
 

 

Diaceutics PLC

("Diaceutics" or the "Company")

 

Directorate change

 

Diaceutics PLC (AIM: DXRX), announces the appointment of Deborah Davis as Non-Executive Chair, effective from 4 January 2021. Deborah has extensive global experience in platform business models, software, fintech, telecoms and e-commerce businesses.

 

After completing her undergraduate studies in Australia, Deborah spent 25 years in CEO and executive roles including 14 years in European and global senior leadership roles at internet platform businesses PayPal and eBay, and technology companies Symantec and Verizon. 

 

She currently holds a number of Non-Executive Director and Board committee positions, including International Personal Finance plc, IDEX Biometrics ASA, Norway, The Institute of Directors UK and Which? Ltd (until 31/12/20). Her previous Board experience also includes private equity based ieDigital. Deborah is a trustee of the Southern African Conservation Trust.

 

Deborah is a Chartered Director and a Fellow of the Institute of Directors. She holds a Bachelor of Applied Science (Electronics) Honours degree from the University of Melbourne and a Sloan Masters in Science (Management) with Distinction from London Business School.

 

Peter Keeling, Chief Executive Officer of Diaceutics said: "I am delighted to attract someone of Deborah's relevant technology background and global experience to join our mission at Diaceutics. With the recent pivotal launch of our DXRX - Precision Testing Network platform, we have truly entered a new chapter in the Company's trajectory and I look forward to working with Deborah to capitalise on this."

 

Information required to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

 

Deborah Lee Davis (Llewelyn), aged 57, is currently or has previously been a director or partner of the following directorships or partnerships within the past five years:

 

Current directorships/partnerships

Historic directorships/partnerships

IPF PLC

IE DIGITAL (formerly Intelligent Environments Europe)

Institute of Directors

IDEX Biometrics ASA

WHICH? LTD

SA CONSERVATION TRUST

 

Save for the information disclosed above, there is no other information to be disclosed on Deborah Davis under Schedule 2(g) of the AIM Rules.

 

Deborah holds no shares in the Company.

 

Enquiries:

 

Diaceutics PLC

www.diaceutics.com

Peter Keeling, Chief Executive Officer

via Walbrook PR

Philip White, Chief Financial Officer

Cenkos Securities plc (Nominated adviser and broker)

+44 (0) 20 7391 8900

Callum Davidson / Giles Balleny

Michael Johnson (Sales)

Walbrook PR

Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com

Anna Dunphy

Mob: +44 (0)7876 741 001

Paul McManus

Mob: +44 (0)7980 541 893

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - a proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries. www.diaceutics.com

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAKKDBNOBDDCBB
Date   Source Headline
19th Dec 20248:09 amRNSHolding(s) in Company
17th Dec 202410:46 amRNSHolding(s) in Company
17th Dec 20247:00 amRNSDiaceutics Wins New $5.1m Contract
10th Dec 20243:14 pmRNSHolding(s) in Company
5th Dec 20247:00 amRNSAwarded UK Research Institute Grant Funding of £1m
3rd Dec 20242:24 pmRNSTotal Voting Rights
28th Nov 20247:00 amRNSExpansion of US Commercial Activities
5th Nov 20247:00 amRNSCapital Markets Webinar
4th Nov 20247:00 amRNSHolding(s) in Company
30th Oct 20242:58 pmRNSPDMR Shareholding/Share Incentive Plan
29th Oct 202410:27 amRNSBoard Change Update
25th Oct 20247:00 amRNSIssue of Share Options/PDMR Shareholdings
24th Oct 202412:53 pmRNSCancellation of Share Premium Account
15th Oct 20247:00 amRNS-RDiaceutics Announces Key Leadership Appointment
7th Oct 20241:19 pmRNSHolding(s) in Company
7th Oct 20247:00 amRNSBlock Listing Return
2nd Oct 20247:00 amRNSPDMR Shareholding/Share Incentive Plan
1st Oct 20247:00 amRNSBoard Changes
17th Sep 20247:00 amRNSH1 2024 Results - Continued Performance & Growth
9th Sep 20247:00 amRNSNotice of Results & Presentations
2nd Sep 20247:00 amRNSAppointment of Nominated Adviser and Broker
30th Aug 20243:45 pmRNSPDMR Shareholding/Share Incentive Plan
27th Aug 20247:00 amRNSDiaceutics Launches Enhanced Rare-Disease Offering
19th Aug 20247:00 amRNSEnterprise Partnership and Launch of PMx
5th Aug 20247:00 amRNSPresenting at Canaccord Genuity Growth Conference
29th Jul 20246:09 pmRNSPDMR Shareholding/SIP and TVR
29th Jul 20247:00 amRNSIssue of Share Options/PDMR Shareholdings
23rd Jul 20247:05 amRNSBoard Changes
23rd Jul 20247:00 amRNSRevenue growth of 24% in H1 with 55% now recurring
11th Jul 20247:00 amRNSSenior Management Appointments
1st Jul 20247:00 amRNSPDMR Shareholding/SIP and Total Voting Rights
24th Jun 20241:15 pmRNSResult of AGM
6th Jun 20247:00 amRNSDiaceutics - Capital Markets Event
29th May 20248:00 amRNSNotice of AGM and Posting of Annual Report
28th May 20247:00 amRNSData to be Presented at 2024 ASCO Annual Meeting
24th May 20243:01 pmRNSPDMR Shareholding/SIP and Total Voting Rights
23rd May 20247:00 amRNSDirector / PDMR Shareholding
21st May 20247:00 amRNSRevenue growth of 22% & order book growth of 57%
16th May 20247:00 amRNSTwo New Enterprise-Wide Engagements
14th May 20247:00 amRNSDiaceutics - Capital Markets Event
1st May 20247:00 amRNSNotice of Results & Presentations
30th Apr 20247:00 amRNSPDMR Shareholding/SIP and TVR
9th Apr 20247:00 amRNSAppointment of Amie Mc Neice as VP of Marketing
5th Apr 20241:40 pmRNSBlock Listing Return
3rd Apr 20247:00 amRNSPDMR Shareholding/Share Incentive Plan
2nd Apr 20247:00 amRNSDirector/PDMR/PCA Shareholding & TR1
21st Mar 20247:00 amRNSSignificant upgrade to Diaceutics' DXRX platform
19th Mar 20247:00 amRNSDiaceutics forms landmark industry Forum
7th Mar 20247:00 amRNSDirector/PDMR Shareholding
1st Mar 20249:00 amRNSPDMR Shareholding / SIP and TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.